Sign inJoin waitlistJoin the waitlist

David Maloney

Medical Director of Cellular Immunotherapy · University of Pennsylvania Health System

Credentials: · · ·

History

Cellular Immunotherapy · University of Pennsylvania Health System
Present
University of Washington School of Medicine
Present
University of Pennsylvania Health System
Present

Cancer Biology, Stanford University
1988–1994
Internal Medicine
Brigham and Women's Hospital
1985–1988
Internal Medicine
1985–1988
Cancer Biology, Stanford University
Stanford University School of Medicine
1981–1985
Chemistry, Whitworth College
1973–1977

Research

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Blood · 2005 · 2,577 citations
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · 2,058 citations
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Journal of Clinical Investigation · 2016 · Last of 23 authors · 1,793 citations

Rainer Storb
116 papers
Brenda Sandmaier
111 papers
TC
Thomas Chauncey
73 papers
MM
Michael Maris
63 papers · 3 as a fellow
Ajay Gopal
53 papers · 2 as a fellow
CT
Cameron Turtle
48 papers
Mohamed Sorror
42 papers
Leona Holmberg
39 papers
PM
Peter Mcsweeney
36 papers
Richard Maziarz
36 papers
Damian Green
34 papers
WB
William Bensinger
34 papers

Grants

Preventing Relapse After Non-Myeloablative Stem Cell Transplantation: The Final Challenge
National Cancer Institute · P01
Project lead · $2.8M · Fred Hutchinson Cancer Center
2000–2019
Anti-cd20 Antibody Therapy of Nhl-- Mechanism of Action
National Cancer Institute · R01
Contact PI · $781.4K · Fred Hutchinson Cancer Research Center
1999–2004
Myeloma Idiotype Vaccines
National Cancer Institute · R55
Contact PI · $100K · Fred Hutchinson Cancer Research Center
1997–1999

Clinical trials

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2016–2021
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Principal investigator · Withdrawn · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2013
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2009–2015
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2004–2011